Following the discovery of the antidepressant properties of ketamine, there has been a recent resurgence in the interest in this NMDA receptor antagonist. Although detailed animal models of the molecular mechanisms underlying ketamine's effects have emerged, there are few MEG/EEG studies examining the acute subanesthetic effects of ketamine infusion in man. We recorded 275 channel MEG in two experiments (n = 25 human males) examining the effects of subanesthetic ketamine infusion. MEG power spectra revealed a rich set of significant oscillatory changes compared with placebo sessions, including decreases in occipital, parietal, and anterior cingulate alpha power, increases in medial frontal theta power, and increases in parietal and cingulat...
Ketamine is a powerful glutamatergic long-lasting antidepressant, efficient in intractable major dep...
Introduction: Increasing preclinical and clinical evidence underscores the role of glutamate in the ...
Ketamine, an NMDA receptor antagonist, is increasingly used to study the link between glutamatergic ...
At subanaesthetic doses, ketamine, an N-methyl-D-aspartate (NMDA) receptor antagonist, has demonstra...
Hypofunctioning of the N-methyl-D-aspartate receptor (NMDA-R) has been prominently implicated in the...
Hypofunctioning of the N-methyl-D-aspartate receptor (NMDA-R) has been prominently implicated in the...
Acute treatment with subanesthetic ketamine, a non-competitive N-methyl-D-aspartic acid (NMDA) recep...
Background: Acute treatment with subanaesthetic doses of NMDA receptor antagonists, such as ketamine...
Background: Subanesthetic dosages of the NMDAR antagonist, S-Ketamine, can cause changes in behavior...
Hypofunction of the N-methyl-d-aspartate receptor (NMDAR) has been implicated as a possible mechanis...
Background. Ketamine has been reported to have efficacy as an antidepressant in several studies of t...
Background: Ketamine is a potent NMDA receptor antagonist with rapid antidepressant properties at su...
Ketamine is a non-competitive N-Methyl-D-Aspartate (NMDA) receptor antagonist whose effect in subane...
Ketamine is a clinical anesthetic and antidepressant. Although ketamine is a known NMDA receptor ant...
Ketamine, an N-methyl-D-aspartate (NMDA) receptor glutamatergic antagonist, has been studied as a mo...
Ketamine is a powerful glutamatergic long-lasting antidepressant, efficient in intractable major dep...
Introduction: Increasing preclinical and clinical evidence underscores the role of glutamate in the ...
Ketamine, an NMDA receptor antagonist, is increasingly used to study the link between glutamatergic ...
At subanaesthetic doses, ketamine, an N-methyl-D-aspartate (NMDA) receptor antagonist, has demonstra...
Hypofunctioning of the N-methyl-D-aspartate receptor (NMDA-R) has been prominently implicated in the...
Hypofunctioning of the N-methyl-D-aspartate receptor (NMDA-R) has been prominently implicated in the...
Acute treatment with subanesthetic ketamine, a non-competitive N-methyl-D-aspartic acid (NMDA) recep...
Background: Acute treatment with subanaesthetic doses of NMDA receptor antagonists, such as ketamine...
Background: Subanesthetic dosages of the NMDAR antagonist, S-Ketamine, can cause changes in behavior...
Hypofunction of the N-methyl-d-aspartate receptor (NMDAR) has been implicated as a possible mechanis...
Background. Ketamine has been reported to have efficacy as an antidepressant in several studies of t...
Background: Ketamine is a potent NMDA receptor antagonist with rapid antidepressant properties at su...
Ketamine is a non-competitive N-Methyl-D-Aspartate (NMDA) receptor antagonist whose effect in subane...
Ketamine is a clinical anesthetic and antidepressant. Although ketamine is a known NMDA receptor ant...
Ketamine, an N-methyl-D-aspartate (NMDA) receptor glutamatergic antagonist, has been studied as a mo...
Ketamine is a powerful glutamatergic long-lasting antidepressant, efficient in intractable major dep...
Introduction: Increasing preclinical and clinical evidence underscores the role of glutamate in the ...
Ketamine, an NMDA receptor antagonist, is increasingly used to study the link between glutamatergic ...